Innoviva, Inc. (INVA) Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Innoviva, Inc. NASDAQ:INVA Healthcare · Biotechnology
Mkt Cap $1.53B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
Innoviva Specialty Therapeutics, a subsidiary of Innoviva (NASDAQ: INVA), will present data from four abstracts at IDWeek 2026 in Washington, D.C., October 21-24.
The presentations cover its two FDA-approved antibiotics, ceftobiprole (ZEVTERA) and zoliflodacin (NUZOLVENCE), including in vitro activity data, pediatric dosing work, and an oral presentation on zoliflodacin's efficacy in gonorrhea patients co-infected with chlamydia.
This is routine post-approval evidence generation supporting commercial uptake rather than a clinical or financial catalyst.
• 13d ago AI analysis › Press Release
Innoviva to Participate in Upcoming Investor Conferences
Innoviva announced management will participate in four September investor conferences: Citi's 2026 Biopharma Back to School Conference, the Cantor Global Healthcare Conference, the H.C. Wainwright 28th Annual Global Investment Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference.
Formats range from 1x1 meetings to a Cantor fireside chat and an H.C. Wainwright presentation on September 14 at 12:00 p.m. ET, with live and archived webcasts available on the company's investor relations site.
The release contains no new financial or operational data — it is a routine investor-relations calendar notice with the company's standard business and product overview.
• 1mo ago AI analysis › Press Release
Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
Innoviva Specialty Therapeutics announced that three of its infectious disease therapies—XACDURO, ZEVTERA, and NUZOLVENCE—have been named finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award.
CEO Pavel Raifeld noted that the nominations serve as a testament to the clinical significance of the portfolio and its efforts to address drug-resistant infections.
The Prix Galien awards recognize pharmaceutical advancements with the potential to improve human health, with winners set to be announced on October 29, 2026.
• 2mo ago AI analysis › Press Release ● Major ⚠ 1
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
Innoviva reported Q2 2026 revenue of $119.6 million, up 19% year-over-year, with Innoviva Specialty Therapeutics (IST) net product sales surging 46% to $51.8 million driven by strong U.S. momentum.
The company remains on track to achieve at least $150 million in IST U.S. net product sales for 2026 and expanded its reach through a new licensing agreement with Dr. Reddy’s Laboratories for XACDURO in emerging markets, alongside the launch of subsidiary Nortiva Bio.
Despite a GAAP net loss of $83.4 million driven by a $161 million mark-to-market decline in Armata Pharmaceuticals, operating income grew to $50.9 million and the company repurchased $31.4 million of stock, ending the quarter with $570.4 million in cash.
• 2mo ago AI analysis › Press Release
Nortiva Bio Launches to Develop Long-Acting Oral Medicines
Innoviva launched Nortiva Bio, a wholly-owned subsidiary focused on developing long-acting oral medicines using the proprietary LYNX drug delivery platform.
Nortiva's lead program is a once-monthly oral contraceptive supported by a $5 million grant from the Gates Foundation, building on preclinical proof of concept.
The company aims to expand its pipeline through industry partnerships, leveraging a platform with over 50 granted patents and previous Phase 3 clinical validation.
• 4mo ago AI analysis › Press Release
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets
Innoviva Specialty Therapeutics has entered into an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories for XACDURO in South and Central America, the Caribbean, Russia, and CIS countries.
Dr. Reddy’s will oversee development, regulatory, and commercialization activities in the licensed territory, while Innoviva retains rights elsewhere and is eligible for upfront payments, milestones, and royalties.
XACDURO is the first FDA-approved antibiotic for treating hospital-acquired bacterial pneumonia caused by Acinetobacter, a pathogen with carbapenem resistance rates exceeding 70% in the target regions.
• 4mo ago AI analysis › Press Release
Innoviva to Participate in Upcoming Investor Conferences
Innoviva announced that management will participate in two investor conferences in June 2026.
The company will hold a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8 and conduct 1x1 meetings at the BTIG Infectious Disease Day on June 16.
A live webcast of the Goldman Sachs event will be available on the company's investor relations website.
• 5mo ago AI analysis › Press Release ● Major
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
Innoviva reported Q1 2026 total revenue of $98.0 million, up 11% year-over-year, driven by a 37% increase in IST net product sales to $41.4 million.
Net income was $186.6 million, or $2.52 per share, bolstered by a $191.2 million favorable change in the fair value of strategic investments.
The company repurchased 971,066 shares for $20.4 million under its $125 million authorization and remains on track to launch NUZOLVENCE in the second half of 2026.
• 5mo ago AI analysis › 
